Provided by Tiger Trade Technology Pte. Ltd.

Defiance Daily Target 2X Long LLY ETF

23.85
-0.2800-1.16%
Post-market: 23.950.1000+0.42%19:49 EDT
Volume:182.33K
Turnover:4.38M
Market Cap:86.46M
PE:- -
High:24.65
Open:24.32
Low:23.56
Close:24.13
52wk High:31.19
52wk Low:14.51
Shares:3.63M
Float Shares:3.63M
Volume Ratio:0.88
T/O Rate:5.03%
Dividend:0.70
Dividend Rate:2.95%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Bayer Bets $2.2 Billion That America Is Still The Best Place To Make Drugs

Macro World​
·
39 mins ago

23.3% Vs 14.8%: Lilly's New Data Just Changed The Obesity Drug Playbook

Bellwether Stocks Movement
·
1 hour ago

Eli Lilly & Co (LLY) Gets a Buy from RBC Capital

TIPRANKS
·
8 hours ago

Former Eli Lilly Exec Sells Wyoming Estate for Close to $39.5 Million

Dow Jones
·
14 hours ago

Eli Lilly announces FDA approves additional indication for Jaypirca

TIPRANKS
·
14 hours ago

Lilly Says FDA Approves Expanded First-Line Cll/sll Use for Jaypirca

Reuters
·
14 hours ago

Lilly's Jaypirca (Pirtobrutinib), the First-and-Only Approved Non-Covalent Btk Inhibitor, Receives Expanded Indication from U.S. FDA for Certain Patients with Previously Untreated Cll/Sll

THOMSON REUTERS
·
14 hours ago

Correction: Top Midday Decliners

MT Newswires Live
·
Yesterday

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Yesterday

Novartis Bets $7.8 Billion On MRNA Beyond Vaccines

Options & Short Sell
·
Yesterday

Sector Update: Healthcare

MT Newswires Live
·
Yesterday

Trump Medicare Drug Pricing Model May Apply to Only Four Companies After Exemptions

Reuters
·
Yesterday

Eli Lilly's Obesity Data Support Broader Portfolio Beyond Tirzepatide, UBS Says

MT Newswires Live
·
Yesterday

Eli Lilly (LLY) Ends Cancer Development Deal with Foghorn Therapeutics

TIPRANKS
·
Oct 01

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (OtherSNYNF), Sagimet Biosciences, Inc. Class A (SGMT) and Eli Lilly & Co (LLY)

TIPRANKS
·
Oct 01

Foghorn Therapeutics Slashes Jobs After Ending Cancer Drug Trials with Ely Lilly

Dow Jones
·
Oct 01

Lilly Says Foundayo Cuts Predicted 10-Year Type 2 Diabetes Risk 57% in Attain-1 Post-Hoc Analysis

Reuters
·
Oct 01

Eli Lilly - Foundayo 17.2 Mg Associated with 57% Reduction in Diabetes Risk, 18% in Cardiovascular Risk Versus Placebo

Reuters
·
Oct 01

Eli Lilly - Foundayo Associated with Reduced Predicted Long-Term Risk of Type 2 Diabetes and Cardiovascular Disease

THOMSON REUTERS
·
Oct 01

The Next Frontier for Obesity Drugs Isn't How Much Weight You Lose, but What Kind

Dow Jones
·
Oct 01